Sorrento Therapeutics Inc (SRNE)
0.02
0.00 (0.00%)
USD |
OTCM |
Apr 25, 16:00
Sorrento Therapeutics Free Cash Flow: -243.21M for June 30, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2023 | -243.21M |
| March 31, 2023 | -271.11M |
| December 31, 2022 | -307.51M |
| September 30, 2022 | -309.00M |
| June 30, 2022 | -328.28M |
| March 31, 2022 | -326.59M |
| December 31, 2021 | -290.69M |
| September 30, 2021 | -237.58M |
| June 30, 2021 | -221.08M |
| March 31, 2021 | -177.54M |
| December 31, 2020 | -166.06M |
| September 30, 2020 | -182.71M |
| June 30, 2020 | -162.85M |
| March 31, 2020 | -173.47M |
| December 31, 2019 | -184.44M |
| September 30, 2019 | -196.98M |
| June 30, 2019 | -172.70M |
| March 31, 2019 | -148.09M |
| December 31, 2018 | -122.96M |
| September 30, 2018 | -118.99M |
| June 30, 2018 | -110.60M |
| March 31, 2018 | -108.49M |
| December 31, 2017 | -110.15M |
| September 30, 2017 | -83.39M |
| June 30, 2017 | -91.64M |
| Date | Value |
|---|---|
| March 31, 2017 | -83.08M |
| December 31, 2016 | -77.79M |
| September 30, 2016 | -76.02M |
| June 30, 2016 | -72.32M |
| March 31, 2016 | -57.37M |
| December 31, 2015 | -45.78M |
| September 30, 2015 | -35.67M |
| June 30, 2015 | -21.70M |
| March 31, 2015 | -29.33M |
| December 31, 2014 | -29.36M |
| September 30, 2014 | -28.81M |
| June 30, 2014 | -26.60M |
| March 31, 2014 | -23.95M |
| December 31, 2013 | -17.42M |
| September 30, 2013 | -11.53M |
| June 30, 2013 | -9.090M |
| March 31, 2013 | -6.011M |
| December 31, 2012 | -4.345M |
| September 30, 2012 | -3.740M |
| June 30, 2012 | -3.212M |
| March 31, 2012 | -4.255M |
| December 31, 2011 | -3.795M |
| September 30, 2011 | -3.144M |
| June 30, 2011 | -2.704M |
| March 31, 2011 | -1.408M |
Free Cash Flow Range, Past 5 Years
-328.28M
Minimum
Jun 2022
-162.85M
Maximum
Jun 2020
-232.46M
Average
-221.08M
Median
Jun 2021
Free Cash Flow Benchmarks
| Scilex Holding Co | -21.04M |
| AIM ImmunoTech Inc | -21.85M |
| Perspective Therapeutics Inc | -37.98M |
| Protalix BioTherapeutics Inc | -2.467M |
| Armata Pharmaceuticals Inc | -55.57M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -55.66M |
| Cash from Investing (Quarterly) | -0.14M |
| Cash from Financing (Quarterly) | 88.81M |
| Free Cash Flow Per Share (Quarterly) | -0.1012 |
| Free Cash Flow to Equity (Quarterly) | -126.87M |
| Free Cash Flow to Firm (Quarterly) | -53.11M |